# **Data Changes for the CCDD DECEMBER Release Candidate 2023**

## **Based on the QA Release Generation** 2024-01-02

|  |  |
| --- | --- |
| Data entered by | J. Hutsul |
| Data checked by |  |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001704 | bismuth subgallate |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9006312 | bismuth subgallate 200 mg chewable tablet |
| 9013949 | cemiplimab 250 mg per 5 mL solution for injection vial |
| 9014333 | pramoxine hydrochloride 0.5 % cutaneous ointment |
| 9003641 | tazarotene 0.05 % cutaneous cream |
| 9002000 | tretinoin 0.025 % cutaneous cream |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. The product has been transferred from DPD to LNHPD.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 9169 | 755893 | APO-PINDOL TAB 15MG (pindolol 15 mg oral tablet) APOTEX INC | Dormant 2023.09.27 |
| 4806 | 544884 | CODEINE PHOSPHATE INJECTION USP (codeine phosphate 30 mg per 1 mL solution for injection ampoule) SANDOZ CANADA INCORPORATED | Dormant 2023.11.29 |
| 3166 | 452696 | DEVROM CHEW TAB 200MG (bismuth subgallate 200 mg chewable tablet) THE PARTHENON COMPANY INC. | Cancelled post-market Expiry 2023.12.31 |
| 97659 | 2486385 | ITCH RELIEF BALM (pramoxine hydrochloride 0.5 % cutaneous ointment) JOHNSON & JOHNSON INC | Cancelled post-market Expiry 2023.12.31 |
| 85094 | 2366061 | JAMP-FOLIC ACID (folic acid 5 mg oral tablet) JAMP PHARMA CORPORATION | Dormant 2023.12.31 |
| 97727 | 2487152 | LIBTAYO (cemiplimab 250 mg per 5 mL solution for injection vial) SANOFI-AVENTIS CANADA INC | Cancelled post-market Expiry 2020.09.30 |
| 5168 | 578576 | STIEVA-A (tretinoin 0.025 % cutaneous cream) GLAXOSMITHKLINE INC | Cancelled post-market Expiry 2023.04.30 |
| 67835 | 2243894 | TAZORAC (tazarotene 0.05 % cutaneous cream) ALLERGAN INC | Cancelled post-market Expiry 2023.12.29 |
| 82321 | 2337630 | TOCTINO (alitretinoin 10 mg oral capsule) GLAXOSMITHKLINE INC | Cancelled post-market Expiry 2023.12.31 |
| 43116 | 2213567 | ZOFRAN (ondansetron (ondansetron hydrochloride dihydrate) 4 mg oral tablet) NOVARTIS PHARMACEUTICALS CANADA INC | Cancelled post-market Expiry 2023.12.31 |

## **Blacklist (on GitHub)**

The following changes have been made to the Exclusion List for the OCTOBER 2023 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 25dd545bf5f5320aa202ca90625e6ad6 | rocuronium bromide 10 mg per mL solution for injection | 100710 | 02517744 | ROCURONIUM BROMIDE INJECTION (rocuronium bromide 10 mg per mL solution for injection) HIKMA CANADA LIMITED | REMOVE |
| 44a1744d2ba75a755d8e0e4e41394a38 | acetaminophen 100 mg per 10 mL solution for injection | 102456 | 2535734 | ACETAMINOPHEN INJECTION (acetaminophen 100 mg per 10 mL solution for injection) B. BRAUN MELSUNGEN AG | ADD |
| 7ce2e3168e31af9a2eadd5428529079e | acetaminophen 500 mg per 50 mL solution for injection | 102457 | 2535742 | ACETAMINOPHEN INJECTION (acetaminophen 500 mg per 50 mL solution for injection) B. BRAUN MELSUNGEN AG | ADD |
| 9014249 | sapropterin dihydrochloride 500 mg per sachet oral powder | 102895 | 2540258 | OZEMPIC (semaglutide 0.68 mg per mL solution for injection) NOVO NORDISK CANADA INC | ADD |
| 5e13f3f6358b9465f4ef5dab9bcbb2f1 | semaglutide 0.68 mg per mL solution for injection | 102445 | 2535610 | REDDY-SAPROPTERIN (sapropterin dihydrochloride 500 mg per sachet oral powder) DR REDDY'S LABORATORIES LTD | ADD |